Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.

Vitale A, Caggiano V, Sbalchiero J, Lopalco G, Tufan A, Ragab G, Sfikakis PP, Dagna L, Batu ED, Ozen S, Conti F, Maiolini F, Bugatti S, Frassi M, Ruscitti P, Morrone M, La Torre F, Cakir IY, Akay N, Kilic Konte E, Laskari K, Bilginer Y, Gattamelata A, Croce J, De Stefano L, Voltarel G, Cipriani P, Maggio MC, Al-Mayouf SM, Fotis L, Rigante D, Sota J, Verrecchia E, Guggino G, La Barbera L, Piga M, Emmi G, Gallizzi R, Conti G, Sfriso P, Bartoloni E, Giacomelli R, Barone P, Olivieri AN, Alemanno A, Lo Gullo A, Direskeneli H, Alibaz-Oner F, Karamanakos A, Prete M, Edrees A, Gavioli F, Parronchi P, Ciccia F, Cardamone C, Hernández-Rodríguez J, Hatemi G, Bes C, Almaghlouth IA, Marhuenda ÁR, Gonzáles-García A, Gaggiano C, De Paulis A, Tezcan ME, Brucato AL, Feist E, Tornero-Romero F, Suzon B, Ogunjimi B, Thabet M, Conforti A, Pucino V, Boyarchuk O, Kovalchuk T, Govoni M, Iagnocco A, Chimenti MS, Moshrif A, Del Giudice E, Carubbi F, Erten Ş, Tharwat S, Hegazy MT, Więsik-Szewczyk E, Torres-Ruiz J, Martín-Nares E, Balistreri A, Fabiani C, Frediani B, Hinojosa-Azaola A, Kasapçopur Ö, Cantarini L

Open source

DOI
10.3389/fphar.2026.1846937
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1846937,
  title = {Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.},
  author = {Vitale A and Caggiano V and Sbalchiero J and Lopalco G and Tufan A and Ragab G and Sfikakis PP and Dagna L and Batu ED and Ozen S and Conti F and Maiolini F and Bugatti S and Frassi M and Ruscitti P and Morrone M and La Torre F and Cakir IY and Akay N and Kilic Konte E and Laskari K and Bilginer Y and Gattamelata A and Croce J and De Stefano L and Voltarel G and Cipriani P and Maggio MC and Al-Mayouf SM and Fotis L and Rigante D and Sota J and Verrecchia E and Guggino G and La Barbera L and Piga M and Emmi G and Gallizzi R and Conti G and Sfriso P and Bartoloni E and Giacomelli R and Barone P and Olivieri AN and Alemanno A and Lo Gullo A and Direskeneli H and Alibaz-Oner F and Karamanakos A and Prete M and Edrees A and Gavioli F and Parronchi P and Ciccia F and Cardamone C and Hernández-Rodríguez J and Hatemi G and Bes C and Almaghlouth IA and Marhuenda ÁR and Gonzáles-García A and Gaggiano C and De Paulis A and Tezcan ME and Brucato AL and Feist E and Tornero-Romero F and Suzon B and Ogunjimi B and Thabet M and Conforti A and Pucino V and Boyarchuk O and Kovalchuk T and Govoni M and Iagnocco A and Chimenti MS and Moshrif A and Del Giudice E and Carubbi F and Erten Ş and Tharwat S and Hegazy MT and Więsik-Szewczyk E and Torres-Ruiz J and Martín-Nares E and Balistreri A and Fabiani C and Frediani B and Hinojosa-Azaola A and Kasapçopur Ö and Cantarini L},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1846937},
  url = {https://doi.org/10.3389/fphar.2026.1846937}
}

RIS

TY  - JOUR
TI  - Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.
AU  - Vitale A
AU  - Caggiano V
AU  - Sbalchiero J
AU  - Lopalco G
AU  - Tufan A
AU  - Ragab G
AU  - Sfikakis PP
AU  - Dagna L
AU  - Batu ED
AU  - Ozen S
AU  - Conti F
AU  - Maiolini F
AU  - Bugatti S
AU  - Frassi M
AU  - Ruscitti P
AU  - Morrone M
AU  - La Torre F
AU  - Cakir IY
AU  - Akay N
AU  - Kilic Konte E
AU  - Laskari K
AU  - Bilginer Y
AU  - Gattamelata A
AU  - Croce J
AU  - De Stefano L
AU  - Voltarel G
AU  - Cipriani P
AU  - Maggio MC
AU  - Al-Mayouf SM
AU  - Fotis L
AU  - Rigante D
AU  - Sota J
AU  - Verrecchia E
AU  - Guggino G
AU  - La Barbera L
AU  - Piga M
AU  - Emmi G
AU  - Gallizzi R
AU  - Conti G
AU  - Sfriso P
AU  - Bartoloni E
AU  - Giacomelli R
AU  - Barone P
AU  - Olivieri AN
AU  - Alemanno A
AU  - Lo Gullo A
AU  - Direskeneli H
AU  - Alibaz-Oner F
AU  - Karamanakos A
AU  - Prete M
AU  - Edrees A
AU  - Gavioli F
AU  - Parronchi P
AU  - Ciccia F
AU  - Cardamone C
AU  - Hernández-Rodríguez J
AU  - Hatemi G
AU  - Bes C
AU  - Almaghlouth IA
AU  - Marhuenda ÁR
AU  - Gonzáles-García A
AU  - Gaggiano C
AU  - De Paulis A
AU  - Tezcan ME
AU  - Brucato AL
AU  - Feist E
AU  - Tornero-Romero F
AU  - Suzon B
AU  - Ogunjimi B
AU  - Thabet M
AU  - Conforti A
AU  - Pucino V
AU  - Boyarchuk O
AU  - Kovalchuk T
AU  - Govoni M
AU  - Iagnocco A
AU  - Chimenti MS
AU  - Moshrif A
AU  - Del Giudice E
AU  - Carubbi F
AU  - Erten Ş
AU  - Tharwat S
AU  - Hegazy MT
AU  - Więsik-Szewczyk E
AU  - Torres-Ruiz J
AU  - Martín-Nares E
AU  - Balistreri A
AU  - Fabiani C
AU  - Frediani B
AU  - Hinojosa-Azaola A
AU  - Kasapçopur Ö
AU  - Cantarini L
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1846937
UR  - https://doi.org/10.3389/fphar.2026.1846937
ER  -

APA

A, V., V, C., J, S., G, L., A, T., G, R., PP, S., L, D., ED, B., S, O., F, C., F, M., S, B., M, F., P, R., M, M., F, L. T., IY, C., N, A., E, K. K., K, L., Y, B., A, G., J, C., L, D. S., G, V., P, C., MC, M., SM, A., L, F., D, R., J, S., E, V., G, G., L, L. B., M, P., G, E., R, G., G, C., P, S., E, B., R, G., P, B., AN, O., A, A., A, L. G., H, D., F, A., A, K., M, P., A, E., F, G., P, P., F, C., C, C., J, H., G, H., C, B., IA, A., ÁR, M., A, G., C, G., A, D. P., ME, T., AL, B., E, F., F, T., B, S., B, O., M, T., A, C., V, P., O, B., T, K., M, G., A, I., MS, C., A, M., E, D. G., F, C., Ş, E., S, T., MT, H., E, W., J, T., E, M., A, B., C, F., B, F., A, H., Ö, K., & L, C. (2026). Association between canakinumab dose and long-term remission in Still's disease: insights from the AIDA network registry.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1846937

Source records